Compass Therapeutics (CMPX) Net Income (2023 - 2026)
Compass Therapeutics' Net Income history spans 4 years, with the latest figure at -$20.3 million for Q1 2026.
- On a quarterly basis, Net Income fell 22.04% to -$20.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$75.2 million, a 28.45% decrease, with the full-year FY2025 number at -$72.8 million, down 28.63% from a year prior.
- Net Income hit -$20.3 million in Q1 2026 for Compass Therapeutics, down from -$18.0 million in the prior quarter.
- Over the last five years, Net Income for CMPX hit a ceiling of -$7.8 million in Q1 2023 and a floor of -$21.1 million in Q2 2025.
- Historically, Net Income has averaged -$14.4 million across 4 years, with a median of -$13.4 million in 2023.
- The widest YoY moves for Net Income: up 8.54% in 2025, down 61.1% in 2025.
- Tracing CMPX's Net Income over 4 years: stood at -$13.4 million in 2023, then fell by 23.55% to -$16.6 million in 2024, then fell by 8.54% to -$18.0 million in 2025, then fell by 12.83% to -$20.3 million in 2026.
- Business Quant data shows Net Income for CMPX at -$20.3 million in Q1 2026, -$18.0 million in Q4 2025, and -$15.8 million in Q3 2025.